TrialAllergy2025

Long-term safety and efficacy of garadacimab for preventing hereditary angioedema attacks: Phase 3 open-label extension study.

Avner Reshef et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.